Trillium Therapeutics (TRIL) Initiates Dosing in Second Phase 1 Trial of TTI-621
Tweet Send to a Friend
Trillium Therapeutics Inc. (NASDAQ: TRIL) announced that it has initiated dosing in its second Phase 1 clinical trial with TTI-621 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
